Abstract:As per the 2022 global tuberculosis (TB) report, TB ranked among the top ten causes of mortality worldwide, surpassing both HIV and malaria in fatalities. It is a communicable disease induced by the Mycobacterium tuberculosis (MTB). Herein the role of molecular modeling tools in the search for new TB therapeutics involves quantitative structure-activity relationship (QSAR), pharmacophore modeling, and molecular docking. In the present work, we compiled approximately 1000 anti-TB candidates from the literature, along with their experimentally determined activities, and classified into three classes based on their biological activities, viz.,pIC, pIC_50, and pMIC_50. All selected compounds were optimized followed by docking them to anti-TB receptors retrieved from the Protein Data Bank. The docking results delineate the nature of interactions between the ligands and their respective receptors, which are prevalently noncovalent, dominated by hydrogen bonds and van der Waals’ interactions. Additionally, DFT-based descriptors were calculated such as constitutional, geometrical, topological, quantum chemical and docking based descriptors basis on their biological activities. The best models were selected on the basis of statistical parameters and were validated by training and test set division.

Corrigendum: Navigating bioactivity space in anti-tubercular drug discovery through the deployment of advanced machine learning models and cheminformatics tools: a molecular modeling based retrospective study

Correction: Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn's Disease and Intestinal Tuberculosis.

Corrigendum: Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes

Corrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives

Corrigendum: Uncovering the Pharmacology of Ginkgo Biloba Folium in the Cell-Type-specific Targets of Parkinson’s Disease with a Deep Learning Algorithm

Corrigendum to "Structure-activity correlations for peptaibols obtained from clade Longibrachiatum of Trichoderma: A combined experimental and computational approach" [Comput Struct Biotechnol J, 21, 2023, 1860-1873]

Correction to "Integrated Network Pharmacology Analysis and Serum Metabolomics to Reveal the Antimalaria Mechanism of Artesunate"

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Corrigendum: Metabolomic analysis in spondyloarthritis: A systematic review

WITHDRAWN: Neural Network and Random Forest Algorithms as Catalysts in QSAR/QSAAR Modeling: Targeting β-Carbonic Anhydrase for Antituberculosis Drug Design

Corrigendum: Targeting p53 misfolding conundrum by stabilizing agents and their analogues in breast cancer therapy: a comprehensive computational analysis

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Corrigendum: Bibliometric and Visual Analysis on Metabolomics in Coronary Artery Disease Research

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration

Corrigendum to: Chloro-s-triazenes-toxicokinetic, Toxicodynamic, Human Exposure, and Regulatory Considerations

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

In-silico studies of anti-tuberculosis drugs using advanced computational techniques

Corrigendum: Identification of novel therapeutic candidates against SARS-CoV-2 infections: An application of RNA sequencing toward mRNA based nanotherapeutics

Corrigendum: NNAN: Nearest Neighbor Attention Network to Predict Drug–Microbe Associations